A new international report released during this week’s Cannabis Europa 2026 conference in London suggests that Europe’s long-dormant cannabis economy is finally awakening. The report, produced by the Global Cannabis Network Collective (GCNC) in partnership with Whitney Economics, examines how medical cannabis expansion, international trade, pharmaceutical manufacturing standards, and evolving regulatory frameworks are transforming the EU and UK into one of the most closely watched regions in the global cannabis industry.
The report, titled What You Need to Know: EU & UK Cannabis Market Update, combines quantitative analysis from Whitney Economics with perspectives from operators, attorneys, consultants, patient advocates, and market leaders across Europe and the United Kingdom. According to the findings, Europe ranks as the second-largest cannabis total addressable market globally by value, despite remaining fragmented across numerous national regulatory systems. The report notes that medical access programs, telemedicine platforms, and international supply chains are rapidly evolving across the region.
“Europe is taking a far more methodical and medically oriented approach to cannabis reform than many markets pursued during earlier expansion cycles,” said Beau Whitney, Chief Economist of Whitney Economics and lead author of the report. “That slower pace may frustrate some operators, but it is also creating a level of structure, predictability, and long-term institutional credibility that is attracting increasing international attention.”
Key findings from the report include Germany continuing to set the pace for cannabis reform in Europe, though mounting imports and pricing pressure are beginning to reshape market economics. The UK medical cannabis market is expanding rapidly through private clinics and telemedicine, despite ongoing barriers tied to physician education, affordability, stigma, and NHS participation. International cannabis trade into Europe continues accelerating, with imports flowing from Canada, Portugal, Latin America, Africa, Australia, and other emerging supply regions. EU GMP standards are increasingly becoming a defining factor for companies seeking long-term participation in European medical cannabis markets.
“Europe is no longer simply reacting to cannabis reform,” said Jillian Reddish, co-founder of GCNC. “The region is increasingly helping shape what the next phase of the global cannabis industry looks like, from international trade standards and medical access models to pharmaceutical manufacturing expectations and long-term market infrastructure.”
The report includes regional market insights and commentary from contributors across Germany, Portugal, Spain, Czechia, and the United Kingdom, highlighting both opportunities and operational complexities. Topics include Germany’s rapidly evolving telemedicine ecosystem, Portugal’s growing role as a cultivation and processing hub, Spain’s medical access reforms, and the Czech Republic’s nascent cannabis policies. The report also notes that pricing compression, already visible across mature cannabis markets globally, is beginning to emerge in Europe as imports increase, supply chains mature, and competitive pressures intensify. Germany, in particular, is showing early signs of wholesale and retail pricing declines tied to expanding imports and inventory growth.
For operators, investors, and policymakers, the report emphasizes the importance of understanding market share, regulatory risk, supply-demand dynamics, and long-term positioning as Europe’s cannabis economy continues evolving. As international markets mature, the industry is increasingly being shaped by the same forces influencing other global commodities: trade routes, logistics, manufacturing standards, supply economics, and price competition. The full report is available at this link.
